Mabion S.A.
Krzysztof Kaczmarczyk is the Chief Executive Officer at Mabion SA since May 2021. Previously, Krzysztof worked as an Advisor to the Management Board at Jastrzębska Spółka Węglowa SA from 2019 to 2020 and also at KGHM Polska Miedź S.A. from 2016 to 2019. Krzysztof held the position of VP, Management Board Member at Emitel from 2011 to 2015. Prior to that, Krzysztof was a Vice President at Credit Suisse from 2010 to 2011. Krzysztof also served as Director at Orange Polska from 2008 to 2010 and as Director at Deutsche Bank from 1999 to 2008. Krzysztof completed their education at SGH Warsaw School of Economics and the University of Warsaw.
Mabion S.A.
2 followers
Mabion S.A. (WSE: MAB) is a Polish biopharmaceutical company founded in 2007, which is undergoing a transformation into a fully integrated contract development and manufacturing organisation (CDMO) providing a broad spectrum of services in the segment of small and medium-sized projects at various stages of development (from early stage discovery to commercial manufacturing). Mabion's competencies include the selection of protein expression technologies, their purification, GMP-standard manufacturing activities (obtaining Active Substances "Drug Substance" and Finished Products "Drug Product"), the development of analytical tools (for structural, functional, physicochemical characterisation), clinical development, clinical analytics and a full range of regulatory activities in the development and operational areas. The company signed a record contract with Novavax in October 2021 for the commercial production of antigen for the COVID-19 vaccine, which it has since steadily expanded through further services under the Statement of Work (SOW) and annexes signed, adding, among other things, another vaccine product based on the Omicron variant. In line with the Strategy announced in April 2023, the Company's objective is to establish itself as a recognisable player in the global contract manufacturing and contract drug development market and to complete the full transformation of Mabion into an integrated biologics CDMO company. Mabion is a public Company, listed on the Warsaw Stock Exchange. For more information about the Company, visit www.mabion.eu.